Multivariate analysis of the correlation of potential risk factors with time to progression (TTP)
| Variable . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Elevated (≥ 3.5 mg/L) β2 microglobulin | 2.55 | 1.29, 5.02 | .007 |
| Presence of 13q− | 1.35 | 0.89, 2.05 | .152 |
| Prior (autologous/allogeneic) SCT | 0.91 | 0.43, 1.93 | .816 |
| Prior bortezomib treatment | 0.71 | 0.38, 1.33 | .294 |
| Prior thalidomide treatment | 0.64 | 0.29, 1.41 | .276 |
| Variable . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Elevated (≥ 3.5 mg/L) β2 microglobulin | 2.55 | 1.29, 5.02 | .007 |
| Presence of 13q− | 1.35 | 0.89, 2.05 | .152 |
| Prior (autologous/allogeneic) SCT | 0.91 | 0.43, 1.93 | .816 |
| Prior bortezomib treatment | 0.71 | 0.38, 1.33 | .294 |
| Prior thalidomide treatment | 0.64 | 0.29, 1.41 | .276 |